Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00945945 · ClinicalTrials.gov registry record · Phase 3
A Study of Duloxetine in Patients With Osteoarthritis Knee Pain
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 424
- Enrollment target
NCT00945945 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 424 participants.
The verdict
NCT00945945, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 424 participants
- Enrollment target
Study Summary
The primary purpose of this study is to determine if duloxetine 60 mg once daily (QD) reduces pain severity in patients with osteoarthritis (OA) knee pain compared with placebo.
Interventions
- DRUG Duloxetine (DLX)
- DRUG Placebo (PLA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00945945
The ClinicalTrials.gov registry entry for NCT00945945 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Duloxetine (DLX) is the first listed.
NCT00945945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00945945 about?
NCT00945945 is a clinical study titled "A Study of Duloxetine in Patients With Osteoarthritis Knee Pain". The primary purpose of this study is to determine if duloxetine 60 mg once daily (QD) reduces pain severity in patients with osteoarthritis (OA) knee pain compared with placebo.
What is the current status of trial NCT00945945?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 424 participants. The study started on 2009-07. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00945945?
The interventions under investigation include: Duloxetine (DLX) (DRUG), Placebo (PLA) (DRUG).
Who is sponsoring clinical trial NCT00945945?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.